MedTrace Logo

Glycaemic Markers in Persons With Type 2 Diabetes on Haemodialysis

NCT03909269 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 88

Last updated 2020-06-30

No results posted yet for this study

Summary

To investigate the correlation between the mean glucose concentration measured by continuous glucose monitoring (CGM) and the estimated mean blood glucose from glycated haemoglobin A1c (HbA1c) in persons with type 2 diabetes and on chronic haemodialysis. Furthermore, the aim is to compare CGM and HbA1c with glycated albumin and fructosamine.

Conditions

  • Diabetic Nephropathy Type 2
  • Type2 Diabetes

Interventions

DEVICE

Continuous glucose monitoring

Continuous glucose monitoring five times over 17 weeks

DIAGNOSTIC_TEST

Glycaemic markers

Measurement of HbA1c by immunoassay (Roche) and chromatography (TOSOH), including glycated albumin and fructosamine.

RADIATION

Erythrocyte life span

Erythrocyte life span measured by Crom-51 labelling over 4 weeks

DEVICE

Carbon monoxide (CO)-rebreathing method

Measurement of total blood volume, plasma volume and erythrocyte volume

Sponsors & Collaborators

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • Rigshospitalet, Denmark

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-04-01
Primary Completion
2020-04-01
Completion
2020-04-01
FDA Device
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03909269 on ClinicalTrials.gov